Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Immunology Product Name: IMU-838
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Immunic Therapeutics
Deal Size: $17.2 million Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2021
The acquisition of the royalties will enable Immunic to realize the full market potential of IMU-838, not only as a treatment for RRMS but also as a potential new therapeutic option for ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis.